MOLECULAR BIOLOGY

Molecular Biology is an international peer reviewed journal that covers a wide scope of problems in molecular, cell and computational biology including genomics, proteomics, bioinformatics, molecular virology and immunology, molecular development biology, molecular evolution and related areals. Molecular Biology publishes reviews, experimental and theoretical works. Every year, the journal publishes special issues devoted to most rapidly developing branches of physical-chemical biology and to the most outstanding scientists.PEER REVIEWMolecular Biology is a peer reviewed journal. We use a double blind peer review format. Our team of reviewers includes over 640 reviewers, both internal and external (98%), from 9 countries (Russia, USA, Germany, Great Britain, Poland, Sweden, Switzerland, China, Australia). The average period from submission to first decision in 2017 was 30 days, and that from first decision to acceptance was 35 days. The rejection rate for submitted manuscripts in 2017 was 72%. The final decision on the acceptance of an article for publication is made by the Editorial Board.Any invited reviewer who feels unqualified or unable to review the manuscript due to the conflict of interests should promptly notify the editors and decline the invitation. Reviewers should formulate their statements clearly in a sound and reasoned way so that authors can use reviewer’s arguments to improve the manuscript. Personal criticism of the authors must be avoided. Reviewers should indicate in a review (i) any relevant published work that has not been cited by the authors, (ii) anything that has been reported in previous publications and not given appropriate reference or citation, (ii) any substantial similarity or overlap with any other manuscript (published or unpublished) of which they have personal knowledge.

MOLECULAR BIOLOGY期刊中文简介

《分子生物学》是一份国际同行评议期刊，涵盖了基因组学、蛋白质组学、生物信息学、分子病毒学与免疫学、分子发育生物学、分子进化及相关领域的分子、细胞和计算生物学的广泛问题。分子生物学出版评论、实验和理论著作。每年，该杂志都会出版一些专刊，专门报道发展最快的物理化学生物学分支和最杰出的科学家。同行评审《分子生物学》是一本同行评议期刊。我们使用双盲同行评审格式。我们的评审团队包括来自9个国家(俄罗斯、美国、德国、英国、波兰、瑞典、瑞士、中国、澳大利亚)的640多名国内外评审人员(98%)。2017年从提交到首次评审的平均周期为30天，从首次评审到验收的平均周期为35天。2017年投稿退稿率为72%。接受发表文章的最终决定由编辑委员会作出。被邀请的审稿人因利益冲突，认为不符合审稿条件或者不能审稿的，应当及时通知审稿人，并予以拒绝。审稿人应以一种合理合理的方式清晰地阐述自己的观点，这样作者才能利用审稿人的观点来完善稿件。必须避免对作者的个人批评。评论者应该显示发表的一篇评论(我)任何相关的工作没有被引用的作者,(2)任何已报道在以前的出版物和没有适当的参考或引用,(2)任何实质性相似或重叠与其他手稿(发表或未发表)的个人知识。